Clinical Trial Update: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial compares CPX-351 to intensive chemotherapy in adults with de novo intermediate- or adverse-risk acute myeloid leukemia, stratified b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING